Escamilla-Ocañas C E, Albores-Ibarra N
Department of Neurology, Division of Vascular Neurology and Neurocritical Care, Baylor College of Medicine, Houston, TX, EE. UU..
División de Ciencias de la Salud, Universidad de Monterrey, San Pedro Garza García, Nuevo León, México.
Neurologia (Engl Ed). 2020 Oct 14. doi: 10.1016/j.nrl.2020.08.007.
Increased intracranial pressure has been associated with poor neurological outcomes and increased mortality in patients with severe traumatic brain injury. Traditionally, intracranial pressure-lowering therapies are administered using an escalating approach, with more aggressive options reserved for patients showing no response to first-tier interventions, or with refractory intracranial hypertension.
The therapeutic value and the appropriate timing for the use of rescue treatments for intracranial hypertension have been a subject of constant debate in literature. In this review, we discuss the main management options for refractory intracranial hypertension after severe traumatic brain injury in adults. We intend to conduct an in-depth revision of the most representative randomised controlled trials on the different rescue treatments, including decompressive craniectomy, therapeutic hypothermia, and barbiturates. We also discuss future perspectives for these management options.
The available evidence appears to show that mortality can be reduced when rescue interventions are used as last-tier therapy; however, this benefit comes at the cost of severe disability. The decision of whether to perform these interventions should always be patient-centred and made on an individual basis. The development and integration of different physiological variables through multimodality monitoring is of the utmost importance to provide more robust prognostic information to patients facing these challenging decisions.
颅内压升高与重型颅脑损伤患者不良的神经学预后及死亡率增加相关。传统上,颅内压降低治疗采用逐步升级的方法,对于对一线干预无反应或颅内高压难治的患者采用更积极的治疗选择。
颅内高压抢救治疗的治疗价值及合适时机一直是文献中持续争论的主题。在本综述中,我们讨论了成人重型颅脑损伤后难治性颅内高压的主要管理选择。我们打算对不同抢救治疗(包括去骨瓣减压术、治疗性低温和巴比妥类药物)最具代表性的随机对照试验进行深入修订。我们还讨论了这些管理选择的未来前景。
现有证据似乎表明,将抢救干预作为最后一线治疗时可降低死亡率;然而,这种益处是以严重残疾为代价的。是否进行这些干预的决定应以患者为中心,根据个体情况做出。通过多模态监测对不同生理变量进行开发和整合对于为面临这些具有挑战性决策的患者提供更可靠的预后信息至关重要。